To be honest, additioanl submissions just make more work for the committee to look through. Nothing ecoool could say is going to make a bit of difference. The trial results and safety data speak for themselves.
I'd call on everyone not to make any submissions of low content to the Committee. Calls by the Yankee for people to make submissions is misguided.
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-277
-
- There are more pages in this discussion • 578 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |